First Patient Dosed in Ph 1 trial of REC-3565 for R/R B-cell Lymphomas
“REC-3565 showed durable tumor regressions in preclinical studies, both as a monotherapy and in combination with a BTK inhibitor. Leveraging our AI-powered Recursion OS platform, which combines physics-based modeling with molecular dynamics and hotspot analysis, we delivered a lead candidate in just 15 months,” said Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion. “Its allosteric design enhances potency, selectivity, and safety, potentially reducing hyperbilirubinemia risks associated with UGT1A1 inhibition seen in other MALT1 inhibitors. This is particularly promising for patients with B-cell malignancies, where unmet needs remain high.”
Share:
More News
“Antengene announced it has entered into a global clinical collaboration with MSD to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate (ADC), and MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025), Antengene
“Advanced esophageal squamous cell carcinoma is a difficult-to-treat disease, and unfortunately overall survival remains low,” said Marjorie Green, MD, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “The initiation of the pivotal Phase 3 IDeate-Esophageal01 clinical trial demonstrates our shared commitment with Daiichi Sankyo to
“Overall response rate (ORR) was 97% (114/117) with a complete response/stringent complete response (CR/sCR) rate of 68% (79/117) and a very good partial response or higher (>VGPR) rate of 85% (100/117), per International Myeloma Working Group (IMWG) criteria as investigator-assessed. Of those evaluable for minimal residual disease (MRD) testing at
“EMA approval of the MIRACLE trial protocol is a huge milestone for us. Although we’re already seeing recruitment in our first non-EU country, we believe that this expansion into the EU really supercharges our recruitment potential,” said Walter Klemp, Chairman and CEO of Moleculin. “Importantly, when combined with the sites
